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A Prospective, Randomized, Blinded, Placebo-Controlled Pilot Study
on the Effect of Enterococcus faecium on Clinical Activity and
Intestinal Gene Expression in Canine Food-Responsive Chronic
Enteropathy
S. Schmitz, B. Glanemann, O.A. Garden, H. Brooks, Y.M. Chang, D. Werling, and K. Allenspach
Background: Canine chronic enteropathies (CE) are believed to be caused by an aberrant immune response towards the
intestinal microbiome. Administration of probiotics can alleviate colitis in people. In vitro effects of the probiotic Enterococ-
cus faecium NCIMB 10415 E1707 (EF) previously have been evaluated using canine cells (e.g., whole blood, intestinal biop-
sies), but data on in vivo efficacy are lacking.
Hypothesis/Objectives: Administration of EF to dogs with food-responsive CE will improve clinical outcome and decrease
the intestinal inflammatory profile.
Animals: Dogs diagnosed with CE were prospectively recruited to receive a hydrolyzed elimination diet plus either a syn-
biotic product containing EF or placebo for 6 weeks. Both veterinary staff and owners were blinded to the treatment.
Methods: Clinical severity index (CCECAI), clinicopathological data and gene expression using intestinal biopsies (TLR2/
4/5/9, IL-17A, IL-22, IL-23p19, RORC, IL-2, IL-12p35, TNFa, IL-4, IFNy, IL-10, TGFb, IL-1b, IL-18, NLRP3, casp-1,
TFF1, TFF3 and PPARy) before and after 6 weeks of treatment were analyzed using linear mixed modeling.
Results: Of the 45 cases recruited, 12 finished the clinical trial. Seven received the synbiotic and 5 the placebo product.
There was no difference between groups or treatments regarding clinical efficacy, histology scores or expression of any of the
investigated genes.
Conclusions and clinical importance: Standard dietary treatment induced rapid clinical response in all cases. Because the study
was underpowered, it was not possible to determine whether or not EF had an additional effect within the time period of 6 weeks.
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Canine chronic enteropathies (CE) are a group ofinflammatory intestinal diseases of unknown
cause.1,2 They usually are defined by response to treat-
ment as food-responsive disease (FRD), antibiotic-
responsive disease (ARD) and (idiopathic) inflammatory
bowel disease (IBD), with the latter also being termed
steroid-responsive disease (SRD).2,3 All of these syn-
dromes manifest in variable degrees and combinations
of gastrointestinal signs (e.g., diarrhea, vomiting, weight
loss, changes in appetite).
Because microbiome changes are consistently found
in dogs with CE,4–6 modification of the intestinal
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microbiome in the form of pre- and pro-biotics seems
to be an interesting treatment option. Several studies
have shown that probiotics can influence key biologi-
cal signaling pathways in immune cells such as NFjB,
MAPK, Akt/PI3K and PPARc.7–11 In humans
with IBD and mice with experimental colitis, respec-
tively, administration of probiotics has been shown to
alleviate intestinal inflammation, prevent relapse or
both by induction of a more tolerant microenviron-
ment.12–14
Knowledge about the usefulness of probiotics in CE
in dogs is limited. Only two studies have evaluated the
in vivo effect of probiotics in dogs with chronic
gastrointestinal diseases.15,16 One used a combination of
different lactobacilli in dogs with FRD compared to
placebo (diet only),15 the other a commercially available
product for humans, which contains eight different
strains of bacteria (lactobacilli, bifidobacteria, strepto-
cocci) in comparison to a combination treatment
consisting of metronidazole and prednisolone.16 In the
FRD study, all dogs improved clinically after treatment,
but intestinal mucosal cytokine patterns were not corre-
lated with clinical outcome or probiotic supplementa-
tion. In the second study, all dogs also improved
clinically, but only in the group treated with probiotics
was an increase in FoxP3 positive regulatory T-lympho-
cytes (Tregs) as well as an increase in the supposedly
protective Faecalibacterium prausnitzii in fecal samples
observed.5,17
Enterococcus faecium NCIMB 10415 E1707 (EF) is
commercially available as a probiotic or synbiotic for
small animals both in Europe and in the USA (the US
strain is SF68). The strain has shown good properties
regarding survival in the upper gastrointestinal tract
(GIT),18 adhesion to canine intestinal mucus and persis-
tence in fecal samples,19 but has not been tested exten-
sively for its immunomodulatory functions. No
information regarding the efficacy of this specific probi-
otic in dogs with CE is available.
The aim of the present work was to assess the clinical
benefit (as measured by the canine chronic enteropathy
clinical activity index CCECAI1) of treatment with a
synbiotic product (containing EF)a in dogs with FRD.
In addition, selected clinicopathological data, intestinal
endoscopic and histology scores and mucosal gene
expression for a variety of genes associated with
microbial recognition and modulation of the immune
system in the intestine were investigated before and
after treatment to assess if EF can induce a more anti-
inflammatory environment.
Materials and Methods
Conduct of a Prospective, Blinded, Placebo-Controlled
Clinical Trial
Ethical Approvals and Products Used. The clinical trial was
approved by the RVC’s Ethics and Welfare Committee (ASPA
number 70/7393) and conducted between June 2010 and May
2013. The synbiotic used contained 1 9 109 cfu EF NCIMB 10415
E1707, FOS and gum Arabica. The placebo consisted of an identi-
cal capsule containing maltodextran.
Inclusion and Exclusion Criteria. Dogs with a history typical for
chronic enteropathy (≥3 weeks of vomiting, diarrhea or both, with
or without weight loss) were included. The diagnosis of chronic
enteropathy was confirmed based on established criteria (no clini-
cally relevant abnormalities on routine hematology, serum bio-
chemistry; trypsin-like immunoreactivity [TLI], canine pancreatic
lipase [cPL] and adrenocorticotropic hormone [ACTH]-stimulation
test results within the reference range; no abnormalities on
abdominal imaging [radiographs, abdominal ultrasound examina-
tion or both]). Histopathologic findings of intestinal mucosal
biopsies had to show lymphoplasmacytic, eosinophilic or mixed
inflammation with or without architectural changes.20,21 Exclusion
criteria were the presence of concurrent diseases or treatment with
antimicrobials, anti-inflammatory drugs or both 7 days before
presentation.
Study Design. Dogs were seen at three separate visits: visit 1
(recruitment), visit 2 (14 ! 3 days after starting the trial medica-
tion) and visit 3 (42 ! 3 days after starting the trial medication;
see Fig 1). The procedures performed at each visit are listed in
Table 1. Patients were randomized (using random permutated
blocks of n = 12 that had been designed before the start of the
studyb) to receive either the synbiotic EF product or placebo in
conjunction with a hydrolyzed protein dietc. All members of staff
involved in the trial (apart from the study monitor, a head nurse)
were blinded to the dogs’ medications.
Assessment of Clinical Severity. Clinical severity was assessed
using the CCECAI at all three visits.1
Endoscopy and Endoscopic Scoring of Lesions
Gastroduodenoscopy and colonoscopy were performed in all
dogs according to standard procedures. Macroscopic endoscopic
scoring was performed using the World Small Animal Veterinary
Association (WSAVA) approved endoscopic examination report.20
Multiple biopsies (15–20) from the duodenum and colon were
taken with a single-use endoscopic biopsy forceps, and 10–15 from
each site were transferred immediately into 2% neutral-buffered
formalin. The remaining biopsies (minimum of 2) were transferred
Table 1. Outline and procedures for each dog at each visit of the clinical trial.
Visit History PE CCECAI CBC/BC UA TLI/cPLI Folate/ cobalamin ACTH stim Faecal Endoscopy and biopsy
1 X X X X X X X X X X
2 X X X Only albumin
3 X X X X X
Visit 1 = before start of treatment, visit 2 = 2 weeks after start of treatment for food-responsive chronic enteropathy with either Entero-
coccus faecium or placebo, visit 3 = 6 weeks after start of treatment. PE, physical exam; CCECAI, canine chronic enteropathy clinical
activity index; CBC, complete blood count; BC, serum biochemistry; UA, urinalysis; ACTH stim, adrenocorticotropin stimulation test; fae-
cal, faecal flotation/sedimentation.
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to RNAlaterd , stored at 4°C for 24 h and then at "80°C until
further processing.
Histopathology
Initial histopathological assessment was performed at the
pathology department of the RVC as part of the routine diagnos-
tic procedure. After finalizing the study, all slides were reviewed
by 1 of the authors (HB), and WSAVA standardized classification
was applied to all slides.20,21 As described previously,22 9 histologic
variables, five representing morphological changes and four repre-
senting inflammatory changes were scored as absent = 0, mild = 1,
moderate = 2, or severe = 3 according to the WSAVA guide-
lines.20,21 The total histology score was recorded. At this stage of
histologic analysis, HB was blinded to original diagnosis, visit
number and treatment group.
Gene Expression from Intestinal Tissues
RNA Extraction and cDNA Synthesis. A single biopsy stored in
RNAlater was thawed and homogenized in lysis buffere using
5 mm stainless steel beadse and a tissue grinderf. Total RNA was
extracted using a commercial kitg including an on-column DNAse
treatment, and eluted in 30 lL nuclease-free water. RNA quantity
and quality was assessed using an automated analyzerh. Reverse
transcription of 1 lg of RNA was performed with a cDNA syn-
thesis kiti, which uses a mixture of oligo-dT and random nonamer
primers.
Generation of Positive Controls and Selection of Reference Gen-
es. Canine sequences for the genes of interest and reference
genes were cloned as described before.23 Primers were designed
based on publically available gene sequences (Genbank,
ENSEMBL) using the Primer3 software (see Table 2).24 A total
of 16 genes were assessed for stability using suitable softwarej
with a commercially available canine reference gene arrayk.
Based on these data, four reference genes were selected for
canine duodenum and five for the colon, respectively (Table 2).
Primers were optimized using standard PCRl. Amplicons were
visualized on a 1.5% agarose gel, purifiedm and cloned into a
holding vectorn for subsequent sequencingo and for qPCR stan-
dards (see below).
Quantitative Polymerase Chain Reaction. qPCR reactions were
carried out in triplicate at a total reaction volume of 20 lL, using
a commercially available reagent mixp and a primer concentration
of 200 nM. Cycling steps were: 95°C for 5 min, then 40 cycles of
94°C for 15 s, 55°C for 10 s, 72°C for 10 s and 80°C for 5 s.
Reaction efficiency was determined using 10-fold dilutions (107
molecules lL"1 to 101 molecules lL"1) of plasmids containing the
cloned amplicon. Melting curves were generated to ensure a single
amplicon had been produced. Averaged gene expression data for
each sample were normalized against the geometric mean of the
reference genes.25
Genes of Interest. Several genes of the innate immune system
interacting with bacteria (Toll-like receptors26,27 [TLRs] 2,4,5, and 9
as well as components of the inflammasome,28 NLRP3, casp-1,
interleukin [IL]-1b and IL-18) and the adaptive immune response in
the intestine were investigated. For the latter, several signature cyto-
kines and transcription factors of different T helper lymphocyte (Th)
cell lines were assessed. These included Th17 cells (IL-17A, IL-22,
IL-23p40, RORC),29,30 Th1 cells (IL-12p35, IL-2, TNFa), Th2 cells
(IFNc and IL-4,31 and Tregs (IL-10 and TGFb).32
Expression of the so-called trefoil factors (TFF), genes associ-
ated with epithelial barrier function and repair,33 also was
assessed. The nuclear receptor PPARc, usually responsible for
blocking the transcription of inflammatory cytokines34 and sup-
posedly especially up-regulated in intestinal epithelial cells by
enterococci,35 was investigated additionally.
Dendrograms and Heatmaps from Gene Expression
Data
To facilitate visualization of gene expression data and changes
in gene expression among visits of the clinical trial, heatmaps were
created using a statistical packageq.
Statistical Analyses
Power Calculation. Clinical severity (as assessed by CCECAI)
was selected as the primary outcome measure. Calculations were
based on a type I error of 0.05 and a type II error of 0.1, which
corresponds to a power of 90%. When assuming a difference
(delta, D) of 1.5 times the sd (r) to be medically relevant, the nec-
essary number of animals in each group (treatment versus placebo)
was determined to be n = 11.
Analysis of Clincopathological, Histological and Gene Expression
Data. Statistical analysis was performed using 2 commercially
available software packagesr,s. Normal distribution was assessed
by inspection of histograms or D’Agostino and Pearson omnibus
normality test. Subsequently, either parametric or non-parametric
tests were performed: A repeated measures model was used to
assess the effect of the treatment interval (before versus after
6 weeks of treatment) and treatment type (EF versus placebo).
Kruskal-Wallis or t-tests were performed to compare clinical and
clinicopathological data, endoscopy and histology scores on visit 1
between treatment groups. Significance was set at P < 0.05.
Results
Patients. A total of 51 possible cases were identified,
45 cases were recruited, and 28 completed visit 1. The
remaining 17 dogs dropped out for several reasons:
Owners changing their mind about participation in the
study without giving specific reasons (n = 5), owners
not wanting endoscopy performed (n = 3), additional
Fig 1. Outline of the clinical trial. Dogs were seen at three separate visits: Visit (V) 1 = recruitment and diagnosis, V2 = after 2 weeks of
treatment with either Enterococcus faecium or placebo, V3 = after 6 weeks of treatment. During the duration of the trial dogs were all fed
the same hydrolysed protein diet.
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medical problems were discovered before endoscopy
was performed (n = 3), with 1 dog developing pro-
nounced neurological symptoms that were deemed more
important than the chronic GIT signs, 1 dog collapsing
after sedation for abdominal ultrasound examination
and 1 dog being diagnosed with concurrent hypothy-
roidism, identification of other diseases causing the GIT
signs (n = 2, with 1 dog having metastatic gastric carci-
noma and the other a pyloric sarcoma), owners not
wanting to complete a 6-weeks food trial (n = 2), own-
ers wanting to perform a food trial before endoscopy
(n = 1) and 1 dog that had an aggressive temperament.
Of the remaining 28 dogs, 16 were withdrawn after visit
1 and did not complete the study. Reasons were: failure
to respond to dietary treatment (n = 6), owner not
wishing to continue with the study without giving spe-
cific reasons (n = 4), owner objecting to a second endos-
copy procedure (n = 2), diagnosis of another condition
responsible for the clinical signs (n = 2; 1 dog with
colonic mucinous adenocarcinoma and 1 dog with pan-
creatitis), dog not eating the hydrolyzed protein diet
(n = 1), and 1 dog being too difficult to handle for a
second period of hospitalization. Thus, a total of 12
dogs finished the clinical trial, including Labrador
Retrievers (n = 6), Golden Retrievers (n = 2) and 1 dog
each of the following breeds: Bracco Italiano, English
Setter, Miniature Schnauzer and Standard Poodle. Six
dogs were intact males, two dogs castrated males, and
four dogs were spayed females. Their median age was
40 months (range, 12–84 months). Seven dogs had been
Table 2. List of genes investigated by quantitative reverse-transcriptase real-time PCR with the respective primers
used.
Gene
product
size Forward primer Reverse primer
Annealing
temp
Accession
number
Casp-1 253 CGACAGACAGCTGGACACAT ATCTGGGCTTTCACATCTGG 55 NM_001003125.1
FoxP3 550 TGG TGC AGT CTC TGG AAC
AG
GGC CTT TGG CTT CTC TTC
TT
60 NM_001168461.1
IFNy 353 TTCAGCTTTGCGTGATTTTG CTGCAGATCGTTCACAGGAA 54.3 NM_001003174.1
IL-10 300 TCTGTTGCTGCCTGGTCCT TGATGTCTGGGTCGTGGTT 54.3 NM_001003077.1
IL-12p35 102 ATGACGGTCCTGTGCCTTAG CTGCCTCTTGGGATCCATTA 55 NM_001003293.1
IL-17A 166 CCGATCTACCTCACCTTGGA TCGCAGAACCAGGATCTCTT 60.2 NM_001165878.1
IL-18 240 GAG GAT ATG CCC GAT TCT
GA
ATC ATG GCC TGG AAC ACT
TC
55 NM_001003169.1
IL-1b 440 GCA GTA CCC GAA CTC ACC
AG
ACA TTT TCC CCA TTG AGG
TG
55 NM_001037971.1
IL-2 243 TCGCACTGACGCTTGTACTT GCACTTCCTCCAGGTTTTTG 58.4 NM_001003305.1
IL-22 254 TCCAGCAGCCCTATATCACC TTGGCTTAGCTTGTTGCTGA 60.2 XM_538274.2
IL-23p19 198 ATGGGACATGTGGACCTACC TAGAGAAGGCTCCCCTGTGA 55 XM_538231.3
IL-4 289 CTCACCTCCCAACTGATTCC TGCTGCTGAGGTTCCTGTAG 56.4 NM_001003159.1
NLRP3 207 GCA ATG CTC TTG GAG ACA
CA
AGA GCA GCA TGA CCC CTA
GA
55 XM_843284.2
PPARy 413 GGATTTCTCCAGCATTTCCA TATGAGACATCCCCACAGCA 59 NM_001024632.2
RORC 289 TGATGGAGACTGAGCACCTG ACCAGAACCACTTCCATTGC 55 XM_540323.3
TFF1 161 GGA GCA CAG GGT GAT CTA
CG
AAC AGC AGC CCT TGT CCT
TA
55 NM_001002992.1
TFF3 105 ACGAACCTGTGCGAGGTG GATGCTGGAGTCGAGCAG 55 NM_001002990.1
TGFb 609 GCATGTGGAGCTGTACCAGA TAGTACACGATGGGCAGTGG 55 NM_001003309.1
TLR2 263 AGTGGCCAGAAAAGCTGAAA ATCCAGTTGCTCCTTCGAGA 54.3 NM_001005264.2
TLR4 200 ATTCCTTTCCGGACAACTCC CTGGAGGGAGAGGAGAGGTT 54.3 NM_001002950.2
TLR5 100 TGGGCGAGCTCTATGACTCT CTGAACGTCTGGTCCTGGAT 55 NM_001197176.1
TLR9 327 GCCTGGAGTACCTGCTCTTG AGGCTTTGGTTTTGGTGATG 55 NM_001002998.1
TNFa 715 TTCTGCCTCAGCCTCTTCTC GCCCTGAGCCCTTAATTCTC 60.2 NM_001003244.4
GAPDHa 194 GGAGAAAGCTGCCAAATATG ACCAGGAAATGAGCTTGACA 55 NM_001003142.1
GUSBa 140 CATGCTGGTCCAGAGCTACA CAGGCTTCAGGAAGGAAGTG 55 NM_001003191.1
HMBSa 112 TCACCATCGGAGCCATCT GTTCCCACCACGCTCTTC 54 XM_546491.3
PPIAa 159 GGGGAGAAGTTTGATGACGA GACCTTGCCAAAGACCACAT 55 XM_532723.3
RPL32a 186 CCTCAGACCTCTGGTGAAGC TTCTTGTTGCTCCCGTAACC 55 NM_001252169.1
SDHAa 412 GGACAGAGCCTCAAGTTTGG GGCATCCTTCCGTAATGA 56.3 XM_535807.3
TBPa 267 GGGACCGCAGCAGATTACTA GCCATAAGGCATCATTGGAC 60 XM_849432.2
ATP5Bb 196 AGCCCATGGTGGTTACTCTG GGCAACAGTCAGTCCAGTCA 55 XM_531639.3
B2Mb 99 ACGGAAAGGAGATGAAAGCA CCTGCTCATTGGGAGTGAA 56 XM_003640047.1
HMBSb 112 TCACCATCGGAGCCATCT GTTCCCACCACGCTCTTC 54 XM_546491.3
PLA2R1b 231 GAAGCCAGCAATGTGTCTCA TCACAAGTGCAGGAGGACAG 55 XM_545489.3
YESb 192 GTCTTTCCATGACGCCATTT TTTGAAACCGTTCACCCTTC 55 NM_001003239.1
aReference genes for the duodenum.
bReference genes for the colon.
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randomly assigned to receive the synbiotic product and
5 to receive placebo.
Clinical and Clinicopathological Data. The majority
of dogs suffered from mixed small and large intestinal
clinical signs (n = 6), 3 had solely small intestinal clini-
cal signs, 2 only chronic vomiting and 1 only large
intestinal diarrhea. Clinical signs at visit 1 were scored
mild to moderate with a median CCECAI of 4 (range,
1–6) in the synbiotic group and 5 (range, 2–7) in the
placebo group, without a significant difference between
groups. In addition, there was no effect of probiotic
treatment on CCECAI at visit 2 or 3 compared to visit
1 (P = 0.72). For both groups combined, CCECAI was
significantly decreased at visits 2 and 3 compared to
visit 1 (P < 0.001), but not between visits 2 and 3
(Fig 2).
There were no significant differences in hematological
and biochemical variables (including TLI, cPL, folate
and cobalamin) between treatment groups at visit 1.
Serum folate concentrations showed a significant
increase with treatment at visit 3 compared to visit 1
(P = 0.012). In addition, there was a significant differ-
ence in serum folate concentrations between the 2 treat-
ment groups at visit 3 (P = 0.012): dogs treated with
placebo had higher serum concentrations of folate
(mean, 21.42 lg L"1; SD, 2.56 lg L"1) than dogs trea-
ted with the synbiotic (mean, 17.02 lg L"1; SD,
1.68 lg L"1).
Endoscopic Findings. Endoscopic WSAVA scores
were low in all areas examined at the initial visit: esoph-
agus median 0 (range, 0–6), stomach median 0 (range,
0–16), duodenum median 1.5 (range, 0–14) and colon
median 0 (range, 0–6). Endoscopy scores were even
lower (but not significantly) at visit 3: esophagus med-
ian 0 (range, 0–1), stomach median 0 (range, 0–3), duo-
denum median 0 (range, 0–6) and colon median 0
(range, 0–1).
Histopathology. Median total WSAVA scoring of his-
topathological findings was 3 for the duodenum (range,
1–5) and 2 (range, 1–5) for the colon at visit 1. At visit
3, the median was 1 (range, 0–8) and 3 (range, 0–4) for
the duodenum and colon, respectively. There was no
significant difference in total scores among visits or
between treatment groups for both sites. In the
duodenum at visit 1, 7 dogs showed a mild increase in
intra-epithelial lymphocytes, 6 dogs showed mild
generalized lymphoplasmacytic infiltration, and 2 dogs
mild eosinophilic inflammation. Duodenal architectural
changes were present in 8 dogs, and included villous
stunting (n = 5), mucosal fibrosis (n = 3), lacteal disten-
sion (n = 2), crypt distension (n = 2) and epithelial
injury (n = 2). Mild lacteal dilatation was identified in 2
cases.
In the colon (visit 1), mild lymphoplasmacytic infiltra-
tion was present in six dogs, mild eosinophilic in two
dogs, marked eosinophilic in one dog, and mild neutro-
philic inflammation in two dogs. Architectural changes in
the colon included crypt hyperplasia (n = 6), crypt dis-
tention and distortion (n = 4), fibrosis and atrophy
(n = 3) and mild surface epithelium injury (n = 1). In 1
dog, the histology of the colon was reported as normal.
Gene Expression. In both duodenum and colon,
TLR2 and TLR4 were more abundantly expressed than
TLR5, and TLR9 was expressed at the lowest level (see
Fig 3). Genes associated with the inflammasome gener-
ally were expressed at a much higher level in the colon
than in the duodenum, especially casp-1 (Fig 4).
There was no expression of IL-17A in any duodenal
sample, although RORC was expressed at a moderate
level (Fig 5). In the colon, IL-17A gene expression was
detectable, but still negligible. Moderate levels of IL-22
and IL-23p19 and high levels of RORC mRNA expres-
sion were present in the colon (see Fig 6).
As observed for other genes, expression levels of Th1
and Th2 cell-related cytokines generally were higher in
the colon than in the duodenum. The IL-12p35 subunit
was most abundantly expressed across all samples, fol-
lowed by IFNy and TNFa. IL-2 was expressed at low
levels and IL-4 showed the lowest expression (see
Figs 5, 6).
Of the genes associated with Tregs, TGFb showed
the highest expression levels, followed by IL-10,
whereas FoxP3 was undetectable (Figs 5, 6).
TFF1 expression was very low in duodenal samples,
whereas TFF3 was highly expressed. The nuclear recep-
tor PPARc showed decreased gene expression at visit 3
compared to visit 1 in the duodenum (possibly more
pronounced in the placebo-treated group than the syn-
biotic-treated dogs), but these differences were not sta-
tistically significant.
For all of the examined genes, there was no signifi-
cant difference in expression with regard to time (before
versus after treatment) or treatment (synbiotic versus
placebo).
Heatmaps of Gene Expression. When assessing all
duodenal or colonic samples, there was no clear effect
of visit or treatment on differences in gene expression,
both by repeat linear mixed modeling including all gene
expression data or by subjective analysis of the cluster-
ing created by the heatmaps and dendrograms (see
Fig 7). Similarly, there was no effect of visit or treat-
ment on differences in gene expression in the colon by
linear mixed modeling, and the heatmap also showed
no clustering (see Fig 7). Gene expression responses in
Fig 2. Canine chronic enteropathy clinical acvtivity index (CCE-
CAI) in 12 dogs participating in the clinical trial at visit 1
(V1 = before treatment), visit 2 (V2 = 2 weeks after start of treat-
ment) and visit 3 (V3 = 6 weeks after start of treatment).
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both tissue types were very variable among individual
dogs.
Discussion
The objective of the current study was to test the
in vivo effects (clinical outcome and changes in gene
expression in intestinal tissues) of the PO administration
of a synbiotic containing the probiotic EF in dogs with
FRD. Although the number of initially recruited dogs
would have likely been sufficient to show a difference
based on the power calculation, unfortunately, the
drop-out rate was considerable. Hence, no additional
clinical benefit of the administration of the synbiotic
could be demonstrated or excluded. Also, no significant
differences in expression of the examined genes were
observed between visit 1 and 3 or between treatment
groups in the duodenum or colon.
A
B
Fig 3. TLR expression in the duodenum (panels A) and colon (panels B) of 12 dogs participating in the clinical trial. V1 = pre-treatment
visit, V3 = after 6 weeks of dietary treatment and either synbiotic (labelled A on the x-axis) or placebo (labelled B on the x-axis) adminis-
tration.
A
B
Fig 4. Expression of genes related to the inflammasome in the duodenum (panels A) and colon (panels B) of 12 dogs participating in the
clinical trial. V1 = pre-treatment visit, V3 = after 6 weeks of dietary treatment and either synbiotic (labelled A on the x-axis) or placebo
(labelled B on the x-axis) administration.
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The study population was consistent with the literature
regarding breed distributaion and age of dogs with
CE.5,36,37 Especially, dogs with FRD seem to be substan-
tially younger than dogs suffering from other forms of
CE.1,38,39 There was no significant correlation between
CCECAI and histopathological scores, a finding that has
been demonstrated before.36,38 However, it is possible
that the dietary trial was not conducted for a sufficient
period of time for morphological changes to resolve.
Interestingly, in all dogs, serum folate concentrations
increased above the reference range with dietary treat-
ment alone. This was more pronounced in the placebo-
treated group than in the synbiotic group. Because
exocrine pancreatic insufficiency had been eliminated in
these dogs, this finding could be indicative of a change
in bacterial composition induced by the dietary inter-
vention, which could have been ameliorated by probiot-
ic treatment. Complementary investigations into the
composition of the intestinal microbiome before treat-
ment unfortunately was not performed. Macroscopic
endoscopy scores and WSAVA histology scores did not
change significantly with treatment, which is consistent
with the literature.1,36,40,41
The gene expression study showed that certain recep-
tors of the innate immune system are differentially
expressed in the canine intestine (TLR2 and 4 are more
abundant than TLR5 and 9). This, as well as the fact
that TFF1 is expressed at low levels, whereas TFF3 is
abundantly present, has been reported before.39,42–44
The general notion that there is no Th cell lineage-asso-
ciated cytokine bias in biopsies from dogs with FRD
also could be confirmed45 and was shown to be true for
both the duodenum and the colon.
Most genes investigated were expressed at a higher
level in the colonic mucosa compared to the duodenum.
This is unlikely due to a better preservation or quality
of colonic samples, because RNA quality and quantity
were assessed for all biopsies and quantification of gene
expression was performed relative to several reference
genes that were assessed for their stability across sam-
ples. The increased gene expression levels in the large
intestine could be associated with the larger number of
bacteria present in the lumen compared to numbers in
the small intestine. However, this also did not change
with treatment for FRD or probiotic supplementation.
Limitations of the study included the fact that
(despite all efforts) it remained underpowered. There-
fore, results regarding the clinical benefit of EF in
canine CE, as well as possible effects on gene expres-
sion, must be interpreted with caution. The clinical trial
was designed to only include dogs with FRD and not
other forms of CE. Including more severely affected
Fig 5. Relative gene expression of cytokines related to differen T helper cell lines in the duodenum of dogs with chronic enteropathy par-
ticipating in the clinical trial. The upper panel shows factors related to Th17 cells (IL-[Interleukin] 22, IL-23p35 and the transcription fac-
tor RORC), the middle panel Th1 (IL-2, IL-12p35) and Th2 (IFNc, IL-4) cytokines, and the lower panel TNFa, which can be classed as
innate cytokine or Th1 related, as well as IL-10 and Transforming growth factor b (TGFb) as representatives of cytokines produced by
regulatory T cells. On the x-axis groups represent different visits (V1 = before treatement, V3 = after 6 weeks of treatment) and different
treatment groups: A = hydrolyzed protein diet plus synbiotic product containing Enterococcus faecium; B = hydrolyzed protein diet plus
placebo.
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dogs (with ARD or SRD) needing a variety of treat-
ments would have required even larger numbers of dogs
in each treatment group and might have made it more
difficult to assess clinical improvement. Even if the
desired 11 dogs had been recruited per treatment group,
the study might have been underpowered. The choice of
the appropriate data set from the literature to use for a
power calculation is challenging, because usually a
decrease of clinical indices of approximately 75% is
considered consistent with remission.46 However, this
has been demonstrated mostly in dogs with idiopathic
IBD (i.e., SRD), which seem to have much higher dis-
ease activity compared to FRD dogs.1 Because the
expected probiotic effect was unknown, power calcula-
tion was difficult to conduct.
Also, the dose of EF chosen to be administered to
the dogs of this clinical trial was recommended by the
manufacturer (1 9 109 CFU once daily). However, lim-
ited data are available to suggest the appropriate
amount of that particular EF strain needed to induce
clinical, immunological or microbiome alterations.
Administration of 2–3 9 109 CFU/day of a different
EF strain resulted in its persistence in feces for
3 months after cessation of the treatment.19 In addition,
culture of feces before and after treatment with EF was
not performed in this study, which potentially could
have been used to ensure owner compliance of capsule
administration. However, because EF can be part of the
normal fecal flora and the probiotic strain cannot be
differentiated from the naturally-occurring EF strains,
the additional benefit of fecal culture is questionable.
In conclusion, this study did not have enough power
to enable a statement regarding a potential additional
effect of EF (given as a synbiotic) on clinical signs or
gene expression in intestinal biopsies in dogs with FRD
within a time period of 6 weeks. More studies using a
larger number of dogs or dogs with different forms of
CE are needed to assess the benefit of probiotics in CE
of dogs. Testing of different probiotic strains for their
clinical or anti-inflammatory properties in comparison
with EF also should be considered.
Footnotes
a Synbiotic D-C; Probiotics International/ Protexin, Somerset, UK
b Microsoft Office, Excel, Microsoft Cooperation, Redmond, USA
Fig 6. Relative gene expression of cytokines related to differen T helper cell lines in the colon of dogs with chronic enteropathy participat-
ing in the clinical trial. The upper panel shows factors related to Th17 cells (IL-[Interleukin] 17, IL-22, IL-23p35 and the transcription fac-
tor RORC), the middle panel Th1 (IL-2, IL-12p35) and Th2 (IFNc, IL-4) cytokines, and the lower panel TNFa, which can be classed as
innate cytokine or Th1 related, as well as IL-10 and Transforming growth factor b (TGFb) as representatives of cytokines produced by
regulatory T cells. On the x-axis groups represent different visits (V1 = before treatement, V3 = after 6 weeks of treatment) and different
treatment groups: A = hydrolyzed protein diet plus synbiotic product containing Enterococcus faecium; B = hydrolyzed protein diet plus
placebo.
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AB
Fig 7. Heatmap and dendrograms depicting the difference in duodenal (A) and colonic (B) gene expression before and after treatment of
12 dogs with food-responsive chronic enteropathy. Examined genes are listed on the x-axis, dog IDs in numbers and with a reference to
treatment (A = synbiotic; B = placebo) are shown on the y-axis. Both clustering of genes and dogs was allowed in these heatmaps based
on gene expression similarities. Red colour indicates an increase in gene expression from visit 1 (before treatment) to visit 3 (6 weeks after
treatment), blue indicates a decrease as depicted by the colour key.
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c Purina Veterinary Diet canine HA Hypo Allergenic, Purina, Nes-
tle, York, UK
d RNAlater (Ambion, UK)
e Qiagen (Manchester, UK)
f Mixer Mill MM300 tissue grinder (Retch, Leeds, UK)
g RNeasy micro kit (Qiagen)
h Eukaryote Total RNA Nano chip, Agilent Bioanalyzer, Agilent
Technologies, Wokingham, UK)
i iScript cDNA synthesis kit (Bio-Rad, Hemel Hampstead, UK)
j qBase/GeNorm software (Biogazelle, Gent, Belgium)
k PrimerDesign Ltd., Southampton, UK)
l Immolase polymerase, Bioline, London, UK)
m Wizard SV Gel and PCR clean-up system (Promega)
n pGemT-Easy vector (Promega)
o Source Bioscience, Cambridge, UK
p SsoFast Evagreen Supermix (Bio-Rad, Hemel Hampstead, UK)
q The R project for statistical computing; www.r-project.org;
“gplots” package; function heatmap.2
r SPSS (IBM SPSS statistics, version 19.0)
s Graph Pad Prism Version 5 (Graph Pad Software Inc., La Jolla,
California, USA)
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